Human Metabolome Technologies, Inc. AI Stock Analysis
Want to see JP:6090 full AI Analyst Report?
Human Metabolome Technologies, Inc. (6090) AI Stock Analysis
Human Metabolome Technologies, Inc.
(TSE/TYO:6090)
The overall score is heavily supported by a highly robust balance sheet and an attractive valuation featuring a solid dividend yield. However, a pronounced technical downtrend and ongoing concerns over operational margin compression limit the score.
Human Metabolome Technologies, Inc. (6090) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.07B
- Dividend Yield
- 3.15%
- Average Volume (3M)
- 4,175
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- 0.31
- Revenue Growth
- 7.98%
- EPS Growth
- 61.76%
- Country
- Japan
- Employees
- 65
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Human Metabolome Technologies, Inc. Business Overview & Revenue Model
Company Description
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, diseas...
How the Company Makes Money
The company makes money primarily by selling metabolomics-related services and solutions to external customers (e.g., pharmaceutical companies, academic institutions, and food/biotech companies). Key revenue streams generally include: (1) fee-for-ser...
Human Metabolome Technologies, Inc. Financial Statement Overview
Summary
Supported by a pristine balance sheet with minimal debt and strong free cash flow generation, though overall performance is weighed down by contracting profit margins and a slight top-line revenue decline.
Income Statement
62PositiveBalance Sheet
88Very PositiveCash Flow
76Positive| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.42B | 1.42B | 1.46B | 1.35B | 1.30B | 1.22B |
| Gross Profit | 868.52M | 868.52M | 922.00M | 869.33M | 859.75M | 840.00M |
| EBITDA | 340.50M | 321.26M | 353.00M | 350.31M | 319.65M | 329.02M |
| Net Income | 200.36M | 200.36M | 256.00M | 243.25M | 285.76M | 267.79M |
Balance Sheet | ||||||
| Total Assets | 2.28B | 2.28B | 2.37B | 2.60B | 2.29B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.44B | 1.44B | 1.59B | 1.79B | 1.66B | 1.50B |
| Total Debt | 103.88M | 103.00M | 110.47M | 226.30M | 226.52M | 233.19M |
| Total Liabilities | 451.39M | 451.39M | 466.13M | 656.84M | 518.91M | 583.39M |
| Stockholders Equity | 1.83B | 1.83B | 1.91B | 1.95B | 1.77B | 1.49B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 148.52M | 225.00M | 202.70M | 168.11M | 177.92M |
| Operating Cash Flow | 0 | 208.58M | 373.00M | 236.79M | 284.96M | 324.03M |
| Investing Cash Flow | 0 | -83.37M | -197.00M | -32.44M | -116.75M | -152.31M |
| Financing Cash Flow | 0 | -281.76M | -369.00M | -73.15M | -13.75M | 80.49M |
Human Metabolome Technologies, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6090, the sentiment is Negative. The current price of 571.00 is below the 20-day moving average (MA) of 583.00, below the 50-day MA of 599.60, and below the 200-day MA of 633.96, indicating a bearish trend. The MACD of -9.13 indicates Positive momentum. The RSI at 36.54 is Neutral, neither overbought nor oversold. The STOCH value of 52.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6090.
Human Metabolome Technologies, Inc. Peers Comparison
Overall Rating
JP:469469Neutral- JP:609069Neutral
JP:338667Neutral
JP:239559Neutral
JP:488248Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4694 | 69Neutral | JPY 147.34B | 19.66 | 6.22% | 3.22% | 3.54% | 10.43% |
| JP:6090 | 69Neutral | JPY 3.39B | 10.83 | ― | 3.15% | 7.98% | 61.76% |
| JP:3386 | 67Neutral | JPY 7.12B | 21.17 | ― | 4.07% | 7.17% | 36.23% |
| JP:2395 | 59Neutral | JPY 51.17B | 9.04 | ― | 4.04% | 1.89% | 22.53% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4882 | 48Neutral | JPY 2.30B | -2.62 | ― | ― | 19.70% | 17.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6090 | Human Metabolome Technologies, Inc. | 571.00 | -57.60 | -9.16% | |
| JP:4694 | BML | 3960.00 | 422.80 | 11.95% | |
| JP:2395 | Shin Nippon Biomedical Laboratories, Ltd. | 1239.00 | -281.65 | -18.52% | |
| JP:3386 | Cosmo Bio Co., Ltd. | 1230.00 | -153.89 | -11.12% | |
| JP:4882 | Perseus Proteomics, Inc. | 126.00 | -173.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026